Publication Year: 2017
-
Concordance between IHC and a new Blood-based Expression Assay for the Detection of PD-L1 in Patients Diagnosed with NSCLC
-
Development of Clinically Relevant Tests from Human Serum Samples: A Look at the Circulating Proteome
-
Mass spectrometry-based test predicts outcome on anti-PD-1 therapy for patients with advanced non-small cell lung cancer with brain metastases
-
Proteomic biomarker analysis of metastatic melanoma patients treated with anti-PD-1 checkpoint blockadeImpact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer
-
The Role Of Proteomic Testing in Improving Prognosis and Care Planning Quality Measures for Lung Cancer
-
INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient management in early and locally advanced NSCLC
-
Faster Turnaround Spurs Clinical Adoption of Liquid Biopsy Tests for Treating Non-Small Cell Lung Cancer
-
Tumor-Associated Autoantibodies: Re-Optimization of Nodify CDT Diagnostic Performance and its Application to Indeterminate Pulmonary Nodules
-
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.
-
An Integrated Risk Predictor for Pulmonary Nodules